CN117957017A - 包含重组重叠肽和天然蛋白质的疫苗制剂 - Google Patents

包含重组重叠肽和天然蛋白质的疫苗制剂 Download PDF

Info

Publication number
CN117957017A
CN117957017A CN202280034836.6A CN202280034836A CN117957017A CN 117957017 A CN117957017 A CN 117957017A CN 202280034836 A CN202280034836 A CN 202280034836A CN 117957017 A CN117957017 A CN 117957017A
Authority
CN
China
Prior art keywords
leu
glu
thr
asn
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280034836.6A
Other languages
English (en)
Chinese (zh)
Inventor
姜石松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Vaccine Medicine
Original Assignee
Oxford Vaccine Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Vaccine Medicine filed Critical Oxford Vaccine Medicine
Publication of CN117957017A publication Critical patent/CN117957017A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20071Demonstrated in vivo effect
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20071Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202280034836.6A 2021-05-11 2022-05-09 包含重组重叠肽和天然蛋白质的疫苗制剂 Pending CN117957017A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB202106713 2021-05-11
GB2106713.7 2021-05-11
PCT/GB2022/051175 WO2022238689A1 (fr) 2021-05-11 2022-05-09 Formulation de vaccin comprenant des peptides chevauchants recombinants et des protéines natives

Publications (1)

Publication Number Publication Date
CN117957017A true CN117957017A (zh) 2024-04-30

Family

ID=81748680

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280034836.6A Pending CN117957017A (zh) 2021-05-11 2022-05-09 包含重组重叠肽和天然蛋白质的疫苗制剂

Country Status (5)

Country Link
US (1) US20240092840A1 (fr)
EP (1) EP4337322A1 (fr)
JP (1) JP2024518565A (fr)
CN (1) CN117957017A (fr)
WO (1) WO2022238689A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0608368D0 (en) 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides
CN105753989A (zh) 2014-12-15 2016-07-13 牛津疫苗医学生物科技(英国)有限公司 人工多抗原融合蛋白及其制备和应用
WO2017120222A1 (fr) * 2016-01-04 2017-07-13 Cour Pharmaceuticals Development Company Inc. Particules encapsulant des protéines hybrides contenant des épitopes liés
CN111671890B (zh) 2020-05-14 2022-08-05 苏州大学 一种新型冠状病毒疫苗及其应用
CN111732637B (zh) 2020-05-25 2022-03-01 上海交通大学 抑制新型冠状病毒SARS-CoV-2感染宿主细胞的多肽及其应用
CN111560054A (zh) 2020-06-16 2020-08-21 哈尔滨吉象隆生物技术有限公司 抑制新型冠状病毒感染的多肽及其筛选方法
CN112618707B (zh) 2020-10-15 2023-07-04 广州达博生物制品有限公司 一种SARS-CoV-2冠状病毒疫苗及其制备方法
CN112226445B (zh) 2020-10-20 2021-05-11 成都欧林生物科技股份有限公司 编码SARS-CoV-2病毒刺突蛋白的核酸及其的应用
CN112220920B (zh) 2020-10-30 2023-06-13 上海泽润生物科技有限公司 一种重组新型冠状病毒疫苗组合物
CN112480217B (zh) 2020-11-30 2022-04-08 广州阿格纳生物医药制造有限公司 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物

Also Published As

Publication number Publication date
WO2022238689A1 (fr) 2022-11-17
US20240092840A1 (en) 2024-03-21
EP4337322A1 (fr) 2024-03-20
JP2024518565A (ja) 2024-05-01

Similar Documents

Publication Publication Date Title
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
KR101983989B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
US10517941B2 (en) Influenza virus vaccines and uses thereof
JP2023524054A (ja) ベータコロナウイルスの予防と治療
JP2003529319A (ja) HIV−1gp41を標的化する広範に中和する抗体を誘発する方法
CN115720581A (zh) 冠状病毒疫苗配制品
CN113666990A (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
WO2022003119A1 (fr) Vaccin contre un coronavirus à réaction croisée
EP4114458A1 (fr) Compositions immunogènes contre le coronavirus-2 responsable du syndrome respiratoire aigu sévère
JP7203015B2 (ja) 免疫原性組成物
US10117923B2 (en) Production of an immunogen using a plant virus
WO2022090679A1 (fr) Polypeptide de coronavirus
US20220354944A1 (en) Coronavirus and influenza compositions and methods for using them
EP4313138A1 (fr) Vaccin sous-unitaire contre le sars-cov-2
EP2987502B1 (fr) Adjuvants peptidiques
CN117957017A (zh) 包含重组重叠肽和天然蛋白质的疫苗制剂
JP2022553258A (ja) インフルエンザウイルスワクチン及びその使用
US20220401546A1 (en) HIV Immunogens, Vaccines, and Methods Related Thereto
CA2548483A1 (fr) Induction d'anticorps neutralisants antiviraux chez les hommes et les animaux
WO2023081861A1 (fr) Expression améliorée par l'intermédiaire d'autotransporteurs
KR20240019213A (ko) 코로나바이러스를 위한 바이러스 유사 입자 백신
CN117999088A (zh) 冠状病毒和流感病毒组合物和其使用方法
CA3100236A1 (fr) Vaccins a adn contre le coronavirus provoquant le syndrome respiratoire aigu severe
CN118159288A (zh) 冠状病毒的病毒样颗粒疫苗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination